Impact of Pre-Transplant Rituximab on Efficacy of Revaccination of Lymphoma Patients after Autologous Hematopoietic Stem Cell Transplantation

Conclusions: Response to reimmunization with inactivated vaccines in lymphoma patients after AHCT is similar to previously reported populations, but prior rituximab exposure appears to impact response.DisclosuresMatasar: Seattle Genetics: Honoraria. Moskowitz: Merck & Co: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Pharmacyclics: Research Funding; Seattle Genetics: Consultancy, Research Funding; Celgene: Consultancy. Sauter: Juno Therapeutics: Consultancy, Research Funding; Sanofi-Genzyme: Consultancy, Research Funding; Spectrum Pharmaceuticals: Consultancy; Novartis: Consultancy; Precision Biosciences: Consultancy; Kite: Consultancy. Shah: Amgen: Research Funding; Janssen: Research Funding. Perales: Abbvie: Other: Personal fees; Incyte: Membership on an entity's Board of Directors or advisory committees, Other: Personal fees and Clinical trial support; Takeda: Other: Personal fees; Merck: Other: Personal fees; Novartis: Other: Personal fees.
Source: Blood - Category: Hematology Authors: Tags: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III Source Type: research